Uncategorized

FDA approves thyroid eye disease treatment 

Published

on

Diabetic eye disease

The US Food and Drug Administration (FDA) has approved Lumvoa (veligrotug-vvze) as a treatment for thyroid eye disease (TED). 

TED is a rare, debilitating autoimmune disease characterised by inflammation and tissue remodelling around and behind the eyes, which can lead to proptosis, diplopia, pain and vision impairment. 

Lumvoa was approved by the FDA under Priority Review and supported by the THRIVE (active TED) and THRIVE-2 (chronic TED) pivotal Phase III clinical trials.  

The treatment is a full antagonist of IGF-1R and the first approved treatment for TED with labelling that includes data for both active and chronic TED. Both the THRIVE and THRIVE-2 clinical trials met their respective primary and all secondary endpoints, consistently demonstrating statistically significant and clinically meaningful improvements at week 15 across all of the key signs and symptoms of TED. 

“With the approval of Lumvoa, we take a significant step forward in providing a meaningful treatment option for people living with thyroid eye disease,” said Steve Mahoney, President and Chief Executive Officer of Viridian, which developed the treatment. 

“Lumvoa was designed with patient needs at the forefront and is Viridian’s first FDA-approved medicine and our first commercial product. This marks an important milestone for us and reflects years of focused execution by the Viridian cross-functional teams.  

“Our commercial and medical affairs teams have been preparing for this moment for a long time, and in particular since receiving Breakthrough Therapy Designation last year. We are ready to support patients and physicians from day one.” 

 

 

 

The post FDA approves thyroid eye disease treatment  appeared first on Drug Discovery World (DDW).

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version